Label: ALOQUIN- aloe vera leaf and iodoquinol gel

  • Category: HUMAN PRESCRIPTION DRUG LABEL

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated October 7, 2009

If you are a healthcare professional or from the pharmaceutical industry please visit this version.

  • SPL UNCLASSIFIED SECTION

    Prescribing Information

  • DESCRIPTION

    Each gram of ALOQUIN contains 1.25% (12.5 mg) Iodoquinol and 1% (10mg) Aloe Polysaccharides. Other ingredients: Purified Water, Carbomer 980, Magnesium Aluminum Silicate, PEG-20 Methyl Glucose Ether, Aminomethyl Propanol 95, Biopeptide, Propylene Glycol, Glycerine, SDA Alcohol 40 B, Benzyl Alcohol, Trolamine, FD&C Blue #1 and D&C Yellow #10.

    Iodoquinol

    Iodoquinol is an antifungal and antibacterial agent. Chemically, Iodoquinol is [5,7-diiodo-8-quinolinol] with the molecular formula (C9H5I2NO) and is represented by the following structural formula:

    Chemical Structure

    Aloe Polysaccharide

    The Aloe Polysaccharide in ALOQUIN is a patented mixture of acetylated mannan aloe polysaccharide. Each purified acetylated mannan polysaccharide of specific molecular weight range and average is composed of the same repeating subunits shown below (where m is mannose, n is galactose and p is glucose monomers):

    Chemical Structure
  • INDICATIONS AND USAGE

    Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: "Possibly" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation.

  • CONTRAINDICATIONS

    ALOQUIN is contraindicated in those patients with a history of hypersensitivity to any components of the preparation.

  • WARNINGS AND PRECAUTIONS

    For external use only. Keep away from eyes. If irritation develops, the use of ALOQUIN should be discontinued and appropriate therapy instituted. Some discoloration of the skin, hair and fabrics may occur, but can be removed with normal cleansing and laundry. Not intended for use on infants or under diapers or occlusive dressings.

    Iodoquinol may be absorbed through the skin and interfere with thyroid function tests. If such tests are contemplated, wait at least one month after discontinuance of therapy to perform these tests. The ferric chloride test for phenylketonuria (PKU) can yield a false positive result if Iodoquinol is present in the diaper or urine. Prolonged use may result in overgrowth of non-susceptible organisms requiring appropriate therapy. Keep out of reach of children.

    Carcinogenesis, Mutagenisis and Impairment of Fertility

    Long term animal studies have not been performed to evaluate the carcinogenic potential of the effect on fertility of Iodoquinol. Mutagenicity studies have not been performed with Iodoquinol.

    Pregnancy Category C

    Animal reproductive studies have not been conducted with ALOQUIN. It is not known whether ALOQUIN can cause fetal harm when administered to pregnant women or can affect reproductive capacity. ALOQUIN should be given to pregnant women only if clearly needed.

    Nursing Mothers

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ALOQUIN is administered to a nursing woman.

    Pediatric Use

    Safety and effectiveness in pediatric patients under the age of 12 have not been established.

  • ADVERSE REACTIONS

    Adverse reactions from topical use of ALOQUIN is expected to be low when used as directed, due to low concentration of Iodoquinol present in this topical gel.

    To achieve the equivalent of a common daily oral dose of nearly 2,000 mg Iodoquinol, one will need to use more than 2 full tubes of 60 g ALOQUIN in a single application. Adverse reactions from oral form of Iodoquinol (nearly 2,000 mg daily) have been reported: various forms of skin eruptions, hives, itching, nausea, vomiting, abdominal cramps, diarrhea, anusitis, fever, chills, headache, vertigo and enlargement of thyroid.

  • DOSAGE AND ADMINISTRATION

    Apply to affected areas 3-4 times daily or as directed by a physician. Follow your physician's directions regarding length of treatment after symptoms resolve.

  • HOW SUPPLIED

    NDC # 68040-706-1660 gram gel tube
    NDC # 68040-706-011 gram gel individual pack
    NDC # 68040-706-0810-count carton of 1 gram gel sample packs - not for resale

    Each 1 gram gel pack contains multiple doses depending on the surface area treated.

    STORAGE

    Store at room temperature 15°-30°C (59°-86°F). Keep tightly closed.

  • SPL UNCLASSIFIED SECTION

    Rx ONLY
    www.aloquin.com

    Manufactured for:
    Primus Pharmaceuticals, Inc.
    Scottsdale, AZ 85251
    www.primusrx.com

    Manufactured by:
    Sonar Products, Inc.
    Carlstadt, NJ 07072

    U.S. Patents #6,436,679; #6,271,214; #6,133,440; #5,925,357; #5,902,796; #5,708,038; #5,703,060; #5,468,737; other patents pending.
    ©2009 Primus Pharmaceuticals, Inc. All rights reserved.

    ISS.0309 #15905

  • PRINCIPAL DISPLAY PANEL - 60g Carton

    NDC 68040-706-16

    AloQuinGEL

    1.25% iodoquinol • 1% aloe polysaccharides

    Contains Moisturizers • For Dermatological Use Only

    Rx Only

    Biopeptide Aloe Complex™
    Deeper Penetration • Patented Formula

    Net Wt. 60g

    PRINCIPAL DISPLAY PANEL - 60g Carton
  • INGREDIENTS AND APPEARANCE
    ALOQUIN 
    aloe vera leaf and iodoquinol gel
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:68040-706
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Aloe Vera Leaf (UNII: ZY81Z83H0X) (Aloe Vera Leaf - UNII:ZY81Z83H0X) Aloe Vera Leaf10 mg  in 1 g
    Iodoquinol (UNII: 63W7IE88K8) (Iodoquinol - UNII:63W7IE88K8) Iodoquinol12.5 mg  in 1 g
    Product Characteristics
    ColorGREENScore    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:68040-706-161 in 1 BOX
    160 g in 1 TUBE
    2NDC:68040-706-011 g in 1 PACKET
    3NDC:68040-706-0810 in 1 BOX
    31 g in 1 PACKET
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Unapproved other07/06/2009
    Labeler - Primus Pharmaceuticals (130834745)
    Establishment
    NameAddressID/FEIBusiness Operations
    Sonar Products, Inc104283945MANUFACTURE